ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Merus NV

Merus NV (2GH)

41.40
0.00
( 0.00% )
Updated: 01:32:04
Realtime Data

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
41.40
Bid
41.00
Ask
41.80
Volume
0.00
0.00 Day's Range 0.00
21.40 52 Week Range 58.50
Previous Close
41.40
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
127
Financial Volume
-
VWAP
-

2GH Latest News

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit Petosemtamab bekannt

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit...

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia – Les données...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

Merus annonce sa participation aux prochaines journées Investisseurs

Merus annonce sa participation aux prochaines journées Investisseurs UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 07 nov. 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), une...

Merus hält Vorträge auf bevorstehenden Investorenkonferenzen

Merus hält Vorträge auf bevorstehenden Investorenkonferenzen UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), ein Unternehmen aus...

La FDA octroie à Merus un report de la date PDUFA pour le zénocutuzumab

La FDA octroie à Merus un report de la date PDUFA pour le zénocutuzumab UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 05 nov. 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), ci-après...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.8-4.1666666666743.2474319244.19451697DE
4-8.6-17.25051.540.411744.74603537DE
12-3.8-8.4070796460245.251.540.412747.17167127DE
26-6.8-14.107883817448.257.540.415948.57608533DE
5218.4802358.521.39999917344.34418355DE
15617.673.949579831923.858.51916742.00023485DE
26017.673.949579831923.858.51916742.00023485DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
70ULion Electric Co The
0.4504 €
(41.37%)
11.9k
TE9Teco 2030 ASA
0.047 €
(31.28%)
424.75k
C62Chariot Limited
0.031 €
(29.17%)
3.5k
EJ7Energy Resources of Australia
0.0025 €
(25.00%)
113.5k
A6NAsana Inc
17.70 €
(21.23%)
1.66k
AXIAtos SE
0.0027 €
(-98.63%)
309.02M
W47Grid Battery Metals Inc
0.0115 €
(-39.47%)
7
3RITurmalina Metals Corp
0.0156 €
(-38.58%)
1.3k
4APApollo Minerals Ltd
0.0055 €
(-35.29%)
270.7k
PQWNPacific Ridge Exploration Ltd
0.0105 €
(-32.26%)
1,000
AXIAtos SE
0.0027 €
(-98.63%)
309.02M
D7GNel ASA
0.2653 €
(-0.64%)
1.55M
TUI1Tui AG
8.41 €
(1.23%)
1.49M
JT71Australian Vanadium Limited
0.0069 €
(-11.54%)
590k
DBKDeutsche Bank AG
17.07 €
(0.73%)
554.6k

Discussion

View Full Feed
MasterBlastr MasterBlastr 5 minutes ago
United Healthcare did at least as well . . . get with the program.
Mother Lode Mother Lode 5 minutes ago
"Gas Prices Set for a Breakout in 2025"

https://oilprice.com/Energy/Natural-Gas/Gas-Prices-Set-for-a-Breakout-in-2025.html
REI
TrendTrade2016 TrendTrade2016 7 minutes ago
AFTERHOURS THE SIGNALS CAME IN STRONG
UPC
capgain capgain 8 minutes ago
GM Larry, it's a good day to stay inside. We just hit 31 here. Heatwave! lol
TrendTrade2016 TrendTrade2016 9 minutes ago
UPC CHINA POST SPLIT MONSTER
UPC
INFINITI INFINITI 11 minutes ago
Why the drop 
ORIS
sand sand 12 minutes ago
Thanks for the constant encouragement. I appreciate it and all that you share here. Hope very much you stay safe. Used to live in Cali so understand.
SPY
GolfnutBoston GolfnutBoston 13 minutes ago
Richie, hopefully you have some tennis planned for the weekend. :-)
28 degrees here, too much frost delay for golf these days. Cape Cod is a little warmer so we sometimes golf there because courses are open all year round even though it's 15 degree wind chill factor along the ocean. 
G
AFFU
baltimorebullet baltimorebullet 13 minutes ago
IMHO the future has never looked brighter for Anavex.
AVXL
kittycattttt kittycattttt 17 minutes ago
Down :-/
DOGEUSD
baltimorebullet baltimorebullet 18 minutes ago
Totally agree.
If the share price gets above 10 between now and then you have choices the 20's don't have.
If they were Jan.2027(or even June 2026). calls I like the 20's, as is, I like the 10's too.
AVXL
anabu9 anabu9 18 minutes ago
https://www.soundhound.com
SOUN
bud_fox bud_fox 19 minutes ago
3 mil+ traded at 5am. Let's roll...
SOUN
MoneyMaker111 MoneyMaker111 23 minutes ago
AMC to $10/share "very very soon" -Analysts

$AMC ( bullish / apish )
#AMC ( bullish / apish )
AMC
Enterprising Investor Enterprising Investor 23 minutes ago
The deal was designed to be cleansing.

However, the board appears to have created more problems for themselves.

They had a duty to disclose that they were looking to sell the trust or that an offer had been received.

I'm not a lawyer, but I hope for our s
Bigstud is here Bigstud is here 25 minutes ago
Wow!!
HMBL
JPetroInc JPetroInc 28 minutes ago
you must be new here

cop a clue and do a lil drill down

cause the clown show left town a while ago

unfortunately you were a little late for the bus

SMH - just add water

Lolzzz
MONI
PennyStockTrader2 PennyStockTrader2 28 minutes ago
thanks Im also asking about the following pipeline scheduled to start work next year in the region around the Brasil field

https://mexicobusiness.news/oilandgas/news/sener-cenagas-approve-mx3-billion-gas-pipeline-project
https://www.promexicoindustry.com/en/article/tamaulipas-b
MRGE
LoveThemStocks LoveThemStocks 30 minutes ago
Goes to show I don't know everything myself: I was agreeing this would be at $3 by today and it's not even close. Oh well.
AMPX
CrypticMinotaur54 CrypticMinotaur54 31 minutes ago
At what price point do you guys think that its a good idea to get back in at the moment? or still too risky
VERI
Enterprising Investor Enterprising Investor 32 minutes ago
cowtown jay cowtown jay 44 minutes ago
'Check Bio-Engine Light?'

Humanigen investors are aware of the lethality of inflammation, and the key contribution lenz can provide in controlling hyper-inflammation.

"A Chicago biomedical research hub backed by Facebook creator Mark Zuckerberg and his wife, Dr. Priscil
Penny2Dime Penny2Dime 47 minutes ago
Yes!
BIEL

Your Recent History

Delayed Upgrade Clock